Arcus Biosciences, Inc. (RCUS)
| Market Cap | 2.18B |
| Revenue (ttm) | 37.87M |
| Net Income (ttm) | -278.39M |
| Shares Out | 70.25M |
| EPS (ttm) | -4.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 635,465 |
| Open | 32.24 |
| Previous Close | 32.37 |
| Day's Range | 31.06 - 33.00 |
| 52-Week Range | 22.36 - 49.10 |
| Beta | 0.84 |
| Analysts | Strong Buy |
| Price Target | 64.40 (+107.1%) |
| Earnings Date | Feb 22, 2022 |
About RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combi...
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for RCUS stock is "Strong Buy." The 12-month stock price forecast is 64.40, which is an increase of 107.14% from the latest price.
News
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...
Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for peo...
Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research C...
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced the closing of Gilead's option exercises to three pr...
Why Arcus Biosciences Stock Vaulted Higher in November
Arcus was one of the few winners in the turbulent biotech space last month.
Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences' Anti-TIGIT Program in Japan and ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for peo...
Arcus Biosciences to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for pe...
Why Are Arcus Biosciences Shares Trading Higher Today?
Gilead Sciences Inc (NASDAQ: GILD) has exercised its options to three programs in Arcus Biosciences Inc (NYSE: RCUS) portfolio, including both anti-TIGIT molecules, domvanalimab, and AB308, as well as e...
Why Arcus Biosciences Stock Is On Fire Today
Gilead Sciences has decided to exercise its options for three of the biotech's oncology programs.
Arcus Biosciences shares rocket premarket after Gilead exercises options for 3 cancer programs for $725 million
Shares of Arcus Biosciences Inc. RCUS, -1.10% rocketed 21% in premarket trading Thursday, after Gilead Sciences Inc. GILD, +0.85% said it's exercising options to three programs in the company's clinical...
Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that Gilead has exercised its options to three progr...
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 1.77% and 2.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for peo...
Arcus Biosciences to Report Third Quarter 2021 Financial Results & Recent Corporate Highlights
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecule and combination medicines for peop...
Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q3 Earnings Expected to Decline
Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 15th
BWB, CDE, ONEM, RCUS, and TMHC have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2021
Arcus Biosciences to Participate at Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management wil...
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Lags Revenue Estimates
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -41.56% and -48.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results fo...
Arcus Biosciences to Participate at the 2021 Wedbush PacGrow Virtual Healthcare Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management wil...
Will Arcus Biosciences, Inc. (RCUS) Report Negative Q2 Earnings? What You Should Know
Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcus Biosciences to Report Second Quarter 2021 Financial Results & Recent Corporate Highlights
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the company wi...
Arcus Biosciences, Inc. (RCUS) Stock Jumps 15.5%: Will It Continue to Soar?
Arcus Biosciences, Inc. (RCUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric...
Why Arcus Biosciences' Big Reveal Wasn't Very Exciting
No news from Arcus Biosciences is bad news for the company and other industry heavyweights.
Here's Why Arcus Biosciences Stock Is Rising Today
Investors expecting Gilead Sciences to license Arcus Biosciences' lead asset could be in for an unpleasant surprise.
Arcus stock jumps 19% after announcing it will move forward with trial for lung-cancer treatment
Shares of Arcus Biosciences Inc. gained 19.8% in trading on Thursday, the day after the company said its experimental lung-cancer PD-L1 treatment demonstrated clinical activity in an open-label, Phase 2...